Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta‐analysis. (24th September 2018)

• Record Type: Journal Article
• Authors: Lattanzi, Simona; Zaccara, Gaetano; Giovannelli, Fabio; Grillo, Elisabetta; Nardone, Raffaele; Silvestrini, Mauro; Trinka, Eugen; Brigo, Francesco
• Is Part Of: Acta neurologica Scandinavica. Volume 139:Number 1(2019)
• Page Start: 33
• Page End: 41
• Publication Date: 2018-09-24
• Subjects: antiepileptic drugs -- focal epilepsy -- monotherapy -- network meta‐analysis; Neurology -- Periodicals; 616.8
• DOI: 10.1111/ane.13025
• Languages: English
• ISSNs: 0001-6314

Abstract

Abstract : Second and third generation AEDs have been directly compared to controlled‐release carbamazepine (CBZ‐CR) as initial monotherapy for new‐onset focal epilepsy. Conversely, no head‐to‐head trials have been performed. The aim of this study was to estimate the comparative efficacy and tolerability of the antiepileptic monotherapies in adults with newly diagnosed focal epilepsy through a network meta‐analysis (NMA). Randomized, double‐blinded, parallel group, monotherapy studies comparing any AED to CBZ‐CR in adults with newly diagnosed untreated epilepsy with focal‐onset seizures was identified. The outcome measures were the seizure freedom for 6 and 12 months, the occurrence of treatment‐emergent adverse events (TEAEs), and the treatment withdrawal due to TEAEs. Mixed treatment comparisons were conducted by a Bayesian NMA using the Markov chain Monte Carlo methods. Effect sizes were calculated as odds ratios (ORs) with 95% credible intervals (CrIs). Four trials were included involving 2856 participants, 1445 for CBZ‐CR and 1411 for the comparative AEDs. Monotherapy AEDs compared to CBR‐CR were levetiracetam (LEV), zonisamide (ZNS), lacosamide (LCM), and eslicarbazepine acetate (ESL). There were no statistical differences in the 6‐ and 12‐month seizure freedom and TEAEs occurrence between LEV, ZNS, LCM, ESL, and CBZ‐CR In the analysis of drug withdrawal due to TEAEs, LCM treatment was associated with a significantly lower discontinuation rate than CBZ‐CR (OR 0.659, 95% CrI 0.428‐0.950). LEV, ZNS, LCM, and ESL are effective initial monotherapy treatments in adult patients with newly diagnosed focal epilepsy and represent suitable alternatives to CBZ‐CR